Unfortunately, the presence of innate or the onset of acquired resistance to EGFR inhibitors remains the most common cause for cancer relapse and mortality, highlighting the importance to investigate the complex network of cancer resistance mechanisms. The gene discussed is EGFR; the disease is cancer.